Literature DB >> 11317963

Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.

J Kutti1, B Ridell.   

Abstract

As to the epidemiology of myeloproliferative disorders (MPD) very little solid information is available in the literature. The present work attempted to study the incidence of MPD in the city of Göteborg, Sweden during a period of ten years. Therefore, retrospectively we assessed the number of subjects afflicted with polycythaemia vera (PV), essential thrombocythaemia (ET) and idiopathic myelofibrosis (IM) over the study period of 1983-1992. The yearly calculated incidence for PV was 2.8 per 100,000 population. For ET and IM the corresponding figures were 1.5 and 0.4, respectively. The results for PV demonstrated the highest incidence rate reported in literature so far. As to ET and IM our results largely agree with what has been reported previously in the literature.

Entities:  

Mesh:

Year:  2001        PMID: 11317963     DOI: 10.1016/s0369-8114(00)00023-7

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  12 in total

1.  Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.

Authors:  M Hultcrantz; A Ravn Landtblom; B Andréasson; J Samuelsson; P W Dickman; S Y Kristinsson; M Björkholm; T M-L Andersson
Journal:  J Intern Med       Date:  2020-01-11       Impact factor: 8.989

2.  Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis.

Authors:  Alen Ostojic; Radovan Vrhovac; Srdan Verstovsek
Journal:  Future Oncol       Date:  2011-09       Impact factor: 3.404

3.  Polycythemia as the first manifestation of Cushing's disease.

Authors:  A Gursoy; A Dogruk Unal; S Ayturk; S Karakus; A Nur Izol; N Bascil Tutuncu; N Guvener Demirag
Journal:  J Endocrinol Invest       Date:  2006-09       Impact factor: 4.256

Review 4.  Polycythaemia vera and essential thrombocythaemia: current treatment strategies.

Authors:  Elisabeth I Penninga; Ole W Bjerrum
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Congenital and acquired polycythemias.

Authors:  Fabian P Siegel; Petro E Petrides
Journal:  Dtsch Arztebl Int       Date:  2008-01-25       Impact factor: 5.594

6.  Development of a highly sensitive method for detection of JAK2V617F.

Authors:  Anna H Zhao; Rufei Gao; Zhizhuang J Zhao
Journal:  J Hematol Oncol       Date:  2011-10-10       Impact factor: 17.388

7.  Ruxolitinib for the treatment of myelofibrosis: its clinical potential.

Authors:  Alen Ostojic; Radovan Vrhovac; Srdan Verstovsek
Journal:  Ther Clin Risk Manag       Date:  2012-03-01       Impact factor: 2.423

8.  The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms.

Authors:  Carol Ann Gross-Davis; Karyn Heavner; Arthur L Frank; Craig Newschaffer; Judith Klotz; Regina M Santella; Igor Burstyn
Journal:  Int J Environ Res Public Health       Date:  2015-02-24       Impact factor: 3.390

9.  Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms.

Authors:  Tetsuro Yokokawa; Tomofumi Misaka; Yusuke Kimishima; Kento Wada; Keiji Minakawa; Koichi Sugimoto; Takafumi Ishida; Soji Morishita; Norio Komatsu; Kazuhiko Ikeda; Yasuchika Takeishi
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

10.  Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.

Authors:  Amos Gaikwad; Josef T Prchal
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.